Results 21 to 30 of about 6,510 (202)

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Frontiers in Pharmacology, 2023
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.
Jiayi Yan, Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou, Shan Mou   +11 more
doaj   +1 more source

Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection [PDF]

, 2023
Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID-19-associated morbidity. In particular, patients with impaired humoral immunity have shown a high risk of persistent infection.
Bartoletti M., Beccacece A., Bussini L., Cantiani A., Casadei B., Chionsini M. C., D'Abramo A., Dentale N., Giannella M., Lazzarotto T., Nicastri E., Pasquini Z., Pellegrini C., Toschi A., Viale P., Vita S., Zinzani P.   +16 more
core   +1 more source

Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study

International Journal of Infectious Diseases, 2023
Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death ...
Ee Vien Low, Mohan Dass Pathmanathan, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +12 more
doaj   +1 more source

Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong [PDF]

, 2023
Importance: Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a common comorbidity in patients with acute COVID-19 and is proven to be a key determinant of COVID-19 prognosis.
Au, Ivan CH, Chung, Matthew SH, Cowling, Benjamin J, Lau, Eric HY, Lau, Kristy TK, Lee, Chi Ho, Lui, David TW, Wong, Carlos KH, Woo, Yu Cho   +8 more
core   +1 more source

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study

Scientific Reports, 2023
We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who ...
Seth Congdon, Zev Narrowe, Nang Yone, Jacob Gunn, Yuting Deng, Priya Nori, Kelsie Cowman, Marjan Islam, Sharon Rikin, Joanna Starrels   +9 more
doaj   +1 more source

Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents [PDF]

, 2022
BACKGROUND: The efficacy on the Omicron variant of the approved early- coronavirus disease 2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are ...
Alessandra, Vergori, Alessandro, Cozzi Lepri, Andrea, Antinori, AnnaRosa, Garbuglia, Claudia, Cimaglia, Eleonora, Lalle, Emanuela, Caraffa, Emanuele, Nicastri, Enrico, Girardi, Eugenia, Milozzi, Fabrizio, Carletti, Fabrizio, Maggi, Francesca, Colavita, Francesco, Vaia, Gaetano, Maffongelli, Ilaria, Mastrorosa, INMI COVID-19 Outpatient Treatment Study Group, Jessica, Paulicelli, Lavinia, Fabeni, Pierluca, Piselli, Raffaella, Libertone, Serena, Vita, Silvia, Rosati, Simone, Lanini, Valentina, Mazzotta   +24 more
core   +2 more sources

Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in patients at high risk [PDF]

, 2023
Background Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable. Methods The impact of each drug was determined via comparisons
Antoniadou, Anastasia, Filippou, Dimitrios, Gaga, Mina, Gerolymatos, Gerasimos, Gkolfinopoulou, Kassiani, Gkova, Maria, Kostaki, Evangelia-Georgia, Kotanidou, Anastasia, Loukides, Stylianos, Mellou, Kassiani, Mossialos, Elias, Paraskevis, Dimitrios, Psalida, Naya, Saroglou, Georgios, Skoutelis, Athanasios, Thiraios, Eleftherios, Tsiodras, Sotirios, Zaoutis, Theoklis, Zografopoulos, Dimitrios   +18 more
core   +1 more source

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life [PDF]

, 2023
Background. Several drugs which are easy to administer in outpatient settings have been authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to prevent hospital admission and death, complementing COVID-19 vaccines.
Francesca Larese Filon, Luca Cegolon, Omar Simonetti, Riccardo Pol, Roberto Luzzati   +4 more
core   +1 more source

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Antibiotics, 2022
Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related hospitalization or death was observed in patients treated with nirmatrelvir ...
Yuan-Pin Hung, Jen-Chieh Lee, Chun-Wei Chiu, Ching-Chi Lee, Pei-Jane Tsai, I-Lin Hsu, Wen-Chien Ko   +6 more
doaj   +1 more source

A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Drug-drug interaction management is complex. Nirmatrelvir/ritonavir is a potent cytochrome P450 (CYP) 3A inhibitor and influences pharmacokinetics of co-administered drugs.
Ayumi Tsuzawa, Yoshiki Katada, Keisuke Umemura, Mitsuhiro Sugimoto, Asami Nishikawa, Yu-ki Sato, Yuko Yoshida, Noriaki Kitada, Atsushi Yonezawa, Daisuke Nakajima, Hiroshi Date, Tomohiro Terada   +11 more
doaj   +1 more source